Frankfurt - Delayed Quote EUR

Ocular Therapeutix, Inc. (0OT.F)

7.41

-0.07

(-0.96%)

As of 8:43:02 AM GMT+1. Market Open.

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity

GlobeNewswire 14 days ago

OCUL
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 First wet AMD registrational trial, SOL-1, completed randomization in December 2024 with topline data anticipated in Q4 2025 Company plans to seek FDA feedback in H1 2025 on clinical trial design for AXPAXLI in NPDR BEDFORD, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a

GlobeNewswire 17 days ago

OCUL
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, future opportunities for AXPAXLI, and a general corporate overview BEDFORD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative ther

GlobeNewswire 23 days ago

OCUL
Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week

It's been a soft week for Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shares, which are down 12%. Despite this, the stock...

Simply Wall St. last month

OCUL
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in San Francisco, CA. 43rd Annual J.P. Morgan Healthcare Conf

GlobeNewswire last month

OCUL
Ocular Therapeutix announces over 300 subjects randomized in SOL-1

Ocular Therapeutix (OCUL) announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI, and the trial is expected to close randomization this week. This is the first registrational clinical trial of AXPAXLI in wet age-related macular degeneration, which remains on track to report topline data in the fourth quarter of 2025. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performin

TipRanks last month

OCUL
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrational trial, SOL-R, while additional sites continue to be activated BEDFORD, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization

GlobeNewswire last month

OCUL
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December. Piper Sandler 36th Annual Healthcare ConferenceFireside Chat Date: Tuesday, December 3rd,

GlobeNewswire 2 months ago

OCUL
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...

Ocular Therapeutix Inc (OCUL) reports robust cash reserves and significant trial advancements, despite regulatory and pricing challenges.

GuruFocus.com 2 months ago

OCUL
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -13.04% and 12.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

OCUL
Ocular Therapeutix: Q3 Earnings Snapshot

BEDFORD, Mass. AP) — Ocular Therapeutix Inc. OCUL) on Thursday reported a loss of $36.5 million in its third quarter.

Associated Press Finance 2 months ago

OCUL
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 conference call and webcast today, November 14th, at 8:00 AM ET BEDFORD, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improvin

GlobeNewswire 2 months ago

OCUL
Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates

Harrow (HROW) delivered earnings and revenue surprises of -140% and 11.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

OCUL
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV. Jefferies London Healthcare Conference 2024Fireside Chat Date: We

GlobeNewswire 2 months ago

OCUL
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

Dr. Saroj brings extensive experience in retinal drug developmentBEDFORD, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that Namrata Saroj, OD, has joined the Company on a full-time basis as Chief Business Officer (CBO). Dr. Saroj

GlobeNewswire 2 months ago

OCUL
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Conference call and webcast to begin at 8:00 AM ETBEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and fi

GlobeNewswire 2 months ago

OCUL
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced accelerated timelines for the SOL-1 Pha

GlobeNewswire 3 months ago

OCUL
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 3 months ago

OCUL

FDMT
Ocular Therapeutix™ to Present at October Ophthalmology Meetings

BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in multiple panels and presentations across three ophthalmology meetings in Chicago, Illinois during October 2024. Presentation & Panel Details (all times CT): Eyecelerator® @

GlobeNewswire 3 months ago

OCUL
Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength

Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks 3 months ago

OCUL

Performance Overview

Return	0OT.F	S&P 500
YTD	-7.05%	+2.78%
1-Year	+60.16%	+23.27%
3-Year	+61.83%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ocular Therapeutix, Inc. (0OT.F)

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix announces over 300 subjects randomized in SOL-1

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix: Q3 Earnings Snapshot

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength

Performance Overview